Please login to the form below

Not currently logged in
Email:
Password:

The evolving biosimilars market

Safety and efficacy doubts remain a challenge

Laurent ChanrouxThe biosimilar market has continued to evolve rapidly in 2015, with the EMA's revised overarching guidelines on biosimilars coming into force and the FDA's approval of biosimilar filgrastim through the new biosimilars pathway (established under the Biologics Price Competition and Innovation Act).

Although these key regulatory developments are expected to greatly facilitate the approval of biosimilars in the near future, recent research from Research Partnership's Therapy Watch revealed that only 47% of rheumatologists interviewed would prescribe a biosimilar within the next six months, and that these agents might eventually only account for 12% of their biologic patients.

Our panel also highlighted the continued need for biosimilar manufacturers to address the remaining doubts about the safety and efficacy of these drugs and work with regulatory agencies and physician organisations to address the lack of clear treatment guidelines governing their use.

Laurent Chanroux

Laurentc@researchpartnership.com
+44 (0)20 8069 5016

21st July 2015

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics